Cost-effectiveness analysis study of HPV testing as a primary cervical cancer screening in Thailand

• Main Authors: Wichai Termrungruanglert, Nipon Khemapech, Tanitra Tantitamit, Suleeporn Sangrajrang, Piyalamporn Havanond, Piyawat Laowahutanont
• Format: Article
• Language: English
• Published: Elsevier 2017-11-01
• Series: Gynecologic Oncology Reports
• Subjects: Cervical cancer; Screening; Human papillomavirus testing; Liquid based cytology; Markov model; Cost effectiveness analysis
• Online Access: http://www.sciencedirect.com/science/article/pii/S2352578917300991

Objectives: The aim of this study is to compare the cost and benefit of four different cervical cancer screening strategies involving primary HPV 16/18 genotyping, hrHPV testing alone and cytology for detecting CIN2+. Methods: Economical analysis using Markov modeling approach to combine the epidemiological data from current population-based study of The National Cancer Institute of Thailand. A cohort of 100,000 hypothetical female population age 30–65 years was simulated in each strategy. The compared strategies are HPV 16/18 genotyping with reflexed cytology, hrHPV testing alone followed by colposcopy, Papanicolaou standard cytology and liquid based cytology followed by colposcopy. The interval of screening was 5 years' interval. The main outcomes were defined as a number of CIN2+ cases and cost per 100,000 women screening over 35 years. Results: Model predictions indicated that, the most cost-effectiveness strategy is hrHPV testing alone by reducing cost and also increase CIN2+ detection rate. It identify an additional 130 cases and decrease cost by 46,950,840 THB (1,394,441 USD) per 100,000 women screened when compared to HPV 16/18 genotyping. Compared with cytology, hrHPV testing decrease cost by 51,279,781 THB (1,523,011 USD) and detected more 506 cases of CIN2+. From sensitivity analysis, the cost of HPV testing, cost of colposcopy, incidence of HPV infection and sensitivity of cytology may affect the results. (1 USD = 33.67 Baht). Conclusion: The results of this cost-effectiveness analysis support the full scale implementation of HPV testing as a primary cervical cancer screening in Thailand.